These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 2053168)

  • 1. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia.
    Müller R; Steffen HM; Brunner R; Saric J; Pollok M; Baldamus CA; Kaufmann W
    Clin Invest Med; 1991 Dec; 14(6):614-22. PubMed ID: 1665406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
    Sapojnikov M; Veksler A; Yagil Y; Kogan J; Turkot S; Boris G; Oren S
    Ren Fail; 2005; 27(2):199-203. PubMed ID: 15807186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
    Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
    Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
    Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of erythropoietin on blood pressure.
    Raine AE; Roger SD
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):76-83. PubMed ID: 1928084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP; Latham D; Abdulhadi M
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin.
    Löw I; Grützmacher P; Bergmann M; Schoeppe W
    Clin Nephrol; 1989 Jan; 31(1):26-30. PubMed ID: 2521587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
    Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
    Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J; Koch KM
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.